拉米夫定抗HBV疗效与血清肝纤维化指标变化的关系

The Relationship between the Virology Response of Lamivudine and the Changes of Serum Fibrosis Markers of Patients with Chronic Hepatitis

目的探讨拉米夫定抗HBV疗效与血清肝纤维化指标变化的关系：方法52例慢性乙型肝炎患者口服拉米夫定100mg／d，治疗至少12个月，在治疗前和治疗后6个月、12个月测定HBVD—NA、血清透明质酸（HA）、层粘蛋白（LN）和Ⅳ型胶原（ⅣC）水平，进行治疗前后比较及抗HBV效果分组比较。结果拉米夫定治疗后3项血清肝纤维化指标明显下降（P〈0．01）；完全应答组、不完全应答组、无应答组之间的差异也有统计学意义（P〈0.01）。结论拉米夫定抗HBV治疗对血清肝纤维化指标有明显降低作用且与抗HBV疗效有关。

Objective To study the relationship between the virology response of lamivudine and the changes of serum fibrosis markers of patients with chronic hepatitis B. Methods 52 patients with HBV infection received lamivudine 100mg/day,oral application for at least 12 months. The levels of serum HBVDNA, hyaluronic acid （HA） ,laminin （LN） , and collagen type Ⅳ （ Ⅳ C） were detected before treatment and after treatment of 6 months, 12 months. The data was analysed before and after treatment and was compared among groups according to the virology response of lamivudine. Results The level of serum HA, LN and Ⅳ C decreased significantly after the treatment of lamivudine （P 〈 0. 01 ） and have obvious difference among groups of complete response,incomplete response and no response of virology response （P 〈 0. 01 ）. Conclusion The serum hepatic fibrosis decrease obviously after lamivudine anti-HBV therapy and is related with the virology response of lamivudine.